Cancer Vaccines Market, By Type (Therapeutic Cancer Vaccines, and Preventive Cancer Vaccines), By Technology (Whole-Cell Cancer Vaccines, Recombinant Cancer Vaccines, Dendritic Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines, and Others), By Application (Cervical Cancer, Prostate Cancer, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Report Code: PMI504323 | Publish Date: March 2024 | No. of Pages: 170

Cancer Vaccines Market Overview

Cancer Vaccines Market accounted for US$ 6.8 billion in 2022 and is estimated to be US$ 34.8 billion by 2032 and is anticipated to register a CAGR of 16.7%. 

Cancer Vaccines are medicines that helps the body to fight against disease. Cancer Vaccines train the immune system for finding and destroying the harmful germs & cells. Cancer Vaccines boost the immune system’s ability for finding and destroying antigens. Cancer cells has molecules called as cancer-specific antigens on their surface. When cancer vaccine is given to a patient, these molecules act as antigens. These molecules when act as antigen tell the immune system for finding and destroying cancer cells which has these molecules on their surface. Personalized Gene Therapy Treatment are made for just one person, where now personalized Cancer Vaccines are also produced from samples of the person’s tumor which are removed during surgery. Mostly, cancer vaccines are offered through clinical trials. FDA has approved ‘sipuleucel-T’ for patient with metastatic prostate cancer. FDA has approved HPV (human papilloma virus) vaccine which will help in preventing cervical cancer. Researchers are testing many cancer vaccines for kidney cancer, leukemia, pancreatic cancer, myeloma, lung cancer, colorectal cancer, brain tumors, breast cancer, etc. Researchers are testing how well a vaccine made from virus altered with HER2 antigen works on bladder cancer. Some types of cancer are caused by HPV (human papilloma virus) which is a common sexually transmitted disease. HPV vaccine helps in protecting against type of HPV that most often causes cancers. HPV vaccine works best when given before any exposure to HPV and thus, helps in preventing new HPV infections. HPV vaccine does not treat any existing infections or diseases. Hepatitis B is a liver disease caused by HBV (Hepatitis B) virus it can lead to liver disease or liver cancer. Hepatitis B vaccine is available for all groups of an individual for preventing HBV infection. Cancer Vaccines offer an attractive approach for synergizing with currently available immunotherapeutics strategies like oncolytic viruses, immune checkpoint inhibitors, and other immune modulators like several cytokines for boosting anti-tumor immunity. However, rising incidence of cancer diseases has fueled the target market growth.

Cancer Vaccines Market Dynamics

 

Rising prevalence of cancer diseases and rapid growth in urbanization has become major driving factor in Cancer vaccines market growth. Smoking has become major risk factor in cause of lung cancer. Urbanization has given rise in air pollution due to industrialization and rising use of vehicles. In 2016, study in European region has determined that about 5% to 7% of lung cancer was observed in people with no smokers and ex-smokers were attributable to higher level of air pollution as expressed by nitrogen dioxide and road bearing heavy traffic. For instance, in June 2016, difference in lung cancer mortality between city and rural areas were observed in Madrid region and the study determined that most urbanized areas of Madrid region were characterized by higher lung cancer mortality rate. Smoking prevalence from 1985 to 2000 was very high in urban areas and thus it was increased with rapid urbanization. Urbanization has caused unhealthy lifestyle, change in diet, obesity, lack of exercise, pollution, late marriages fewer children, no breast feeding or lesser feeding for less duration, early menarche, late menopause, which has become major contribution in rise of breast cancer. According to ‘The World Cancer Report 2020’ it was determined that incidence of breast cancer is consistently rising in India due to high socio-economic status and rapid urbanization. For instance, in 2016, (NIH), the relationship between cancer incidence and urbanization in Iran were conducted by using Quantile Regression. Data obtained by Ministry of Health & Medical Education and relationship between urbanization and cancer morbidity was investigated by quantile regression and determined that breast cancers, pancreas, prostate, colorectal and lung cancers increasing with rate of urbanization. 90th percentile was maximum increase rate of breast cancer. 95th percentile was of prostate cancer, 75th percentile was of colorectal cancer, 95th percentile for lung cancer and 10th percentile for pancreas cancer. According to the results, it was determined that there was significant impact of rising urbanization on cancer morbidity due to risk factors like more pollution in urban areas, poor nutrition food, lack of exercise, smoking, alcohol intake, etc. For instance, in 2020, according to (PMC), urban population was 36.6% to 44.8% in 1970-1994 and expected to increase till 61.1% till 2025. Around 70%-80% of colorectal cancer incidence in urban population occurs due to unhealthy lifestyle and environmental factors. According to data published by United Nations in 2018, about 55% of the world’s population resided in urban areas, and it is projected that this percentage will increase over the forecast period. Preventative cancer vaccines has proven to be successful in reducing burden associated with cancer causing viruses such as HBV (Hepatitis B virus) and HPV (Human Papilloma Virus). Recent development made in understanding molecular mechanisms used by tumor cells for escaping immune surveillance is aiding the development of preventative & therapeutic vaccines which could be effective against various human cancers which are not associated with known etiopathogenic agent. Both Preventive Vaccines and therapeutic cancer vaccines are successfully developed and approved. However, the growth in cancer disease and population in urban areas boosts the demand for Cancer Vaccines market.

Restrains:

Larger or more advanced tumors are difficult to get rid of using only vaccine. Patient who are sick, older, has weak immune system, their bodies do not produce strong immune response after receiving cancer vaccine. This, limits the how well cancer works vaccine. Cancer vaccines may work better for small tumors which are early stage and do not work for larger tumors. Cancer vaccines may cause some side-effects such as flu-like symptoms which includes, fever, fatigue, chilling, nausea, weakness, vomiting, muscle & joint pain, headache, dizziness, etc. Low immunogenicity, immunosuppressive tumor environment and established disease burden are the major challenges for developing cancer vaccines. However, some challenges regarding development of cancer vaccines and side-effects may restrain the target market growth.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Cancer Vaccines Market Segmentation

segmentation - Cancer Vaccines Market

The Cancer Vaccines market is segmented based on technology, application, end-users and region.

On the basis of Type, the Cancer Vaccines market is segmented into Therapeutic Cancer Vaccines, and Preventive Cancer Vaccines. On the basis of technology, the target market is segmented into Whole-Cell Cancer Vaccines, Recombinant Cancer Vaccines, Dendritic Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines, and others. On the basis of application, the target market is segmented into Cervical Cancer, Prostate Cancer, and others.

Regional Insights:

On region the Cancer Vaccines Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements. Moreover, rising incidence of cancer diseases, well developed & robust healthcare infrastructure, rising research & development activities, advanced technological development, and government initiative is anticipated to increase demand for Cancer Vaccines in the region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2022

Forecast period

2022 – 2032

Market representation

Revenue in USD Billion & CAGR from 2022 to 2032

Market Segmentation

By Type - Therapeutic Cancer Vaccines, and Preventive Cancer Vaccines

By Technology – Whole-Cell Cancer Vaccines, Recombinant Cancer Vaccines, Dendritic Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines, and others

By Application - Cervical Cancer, Prostate Cancer, and others

 

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Cancer Vaccines Market report based on type, technology, application, and region:

Cancer Vaccines Market, By Type:

  • Therapeutic Cancer Vaccines
  • Preventive Cancer Vaccines

Cancer Vaccines Market, By Technology:

  • Whole-Cell Cancer Vaccines
  • Recombinant Cancer Vaccines
  • Dendritic Cell Cancer Vaccines
  • Viral Vector & DNA Cancer Vaccines
  • Others

Cancer Vaccines Market, By Application:

  • Cervical Cancer
  • Prostate Cancer
  • Others

Cancer Vaccines Market, By Region:

  • North America
    • Middle East & Africa
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Europe
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • U.S.
    • Canada

Cancer Vaccines Market Key Players

The key players operating the Cancer Vaccines Market includes, Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Merck & Co. Inc., Xiamen Innovax Biotech Co. Ltd., Dendreon Pharmaceuticals LLC., Biomed Lublin S.A., Walvax Biotechnology Co. Ltd., Organon Teknika Corp. LLC., Astellas Pharma Inc., Moderna Inc., and others.

Cancer Vaccines Market Key Issues Addressed

Recent Development:

  • In September 2022, ‘CERVAVAC’ a Quadrivalent Human Papillomavirus Vaccine (qHPV) is developed by Serum Institute of India (SII) & the Department of Biotechnology (DBT) is launched by the Central government of India which is India’s first vaccine against cervical cancer. According to Serum Institute of India (SII), the cost of vaccine is likely to be 200 to 400 per dose.
  • In March 2022, Walvax has won NMPA nods for HPV bivalent vaccine. China’s NMPA has given green light for Walvax’s human papillomavirus (HPV) bivalent vaccine to be used against human papillomavirus (HPV) types 16 and 18 for preventing cervical cancer. These newly developed vaccine has been approved for sale. The manufacturing unit Shanghai Zerun Biotechnology has prepared a production unit base with annual capacity of 15 million doses.

Cancer Vaccines Market Company Profile

  • Serum Institute of India Pvt. Ltd.*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • GlaxoSmithKline Plc.
  • Merck & Co. Inc.
  • Xiamen Innovax Biotech Co. Ltd.
  • Dendreon Pharmaceuticals LLC.
  • Biomed Lublin S.A.
  • Walvax Biotechnology Co. Ltd.*
  • Organon Teknika Corp. LLC.
  • Astellas Pharma Inc.
  • Moderna Inc.,

 “*” marked represents similar segmentation in other categories in the respective section

Cancer Vaccines Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for medical carts Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Technology
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restrains
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Cancer Vaccines Market, By Type
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Therapeutic Cancer Vaccines
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Preventive Cancer Vaccines
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  6. Market Segmentation, By Technology, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Whole-Cell Cancer Vaccines
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Recombinant Cancer Vaccines
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Dendritic Cell Cancer Vaccines
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Viral Vector & DNA Cancer Vaccines
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  7. Market Segmentation, By Application, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Cervical Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Prostate Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  8. Global Market, By Region, 2022 – 2032, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Technology, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Technology, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Technology, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Technology, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Technology, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
      • GCC
      • Israel
      • South Africa
      • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  3. Company Profiles
  • Serum Institute of India Pvt. Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Xiamen Innovax Biotech Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Dendreon Pharmaceuticals LLC.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Biomed Lublin S.A.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Walvax Biotechnology Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Organon Teknika Corp. LLC.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Astellas Pharma Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Moderna Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The Cancer Vaccines Market is segmented into type, technology, application, and region.

Cancer Vaccines Market is driven by factors like rising prevalence of cancer diseases & rate of urbanization.

By region, the Cancer Vaccines market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements.

The key players operating the Cancer Vaccines Market includes, Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Merck & Co. Inc., Xiamen Innovax Biotech Co. Ltd., Dendreon Pharmaceuticals LLC., Biomed Lublin S.A., Walvax Biotechnology Co. Ltd., Organon Teknika Corp. LLC., Astellas Pharma Inc., Moderna Inc., and others.